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Abstract In response to Ca2+ signaling, cytosolic phospholi-
pase A2K (cPLA2K) translocates from the cytosol to the peri-
nuclear membrane, where downstream eicosanoid-synthetic en-
zymes, such as cyclooxygenase (COX), are localized. Although
the spatiotemporal perinuclear colocalization of cPLA2K and
COXs has been proposed to be critical for their functional cou-
pling leading to prostanoid production, de¢nitive evidence for
this paradigm has remained elusive. To circumstantiate this is-
sue, we took advantage of a chimeric cPLA2K mutant harboring
the C2 domain of protein kinase CK, which translocates to the
plasma membrane following cell activation. Transfection analy-
ses of the native or chimeric cPLA2K in combination with COX-
1 or COX-2 revealed that, even though the arachidonate-releas-
ing capacities of native and mutant cPLA2K were comparable,
prostaglandin production by mutant cPLA2K was markedly im-
paired as compared with that by native cPLA2K. We thus con-
clude that the perinuclear localization of cPLA2K is preferen-
tial, even if not obligatory, for e⁄cient coupling with COXs.
, 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Of a number of phospholipase A2 (PLA2) enzymes, includ-
ing the cytosolic PLA2 (cPLA2), secretory PLA2 (sPLA2) and
Ca2þ-independent PLA2 (iPLA2) families, group IVA cPLA2K
plays a central role in the stimulus-coupled release of arachi-
donic acid (AA), a precursor of eicosanoids including prosta-
glandins (PGs) and leukotrienes (LTs) [1,2]. cPLA2K is the
only PLA2 enzyme that shows marked preference for the
sn-2 AA over other fatty acids [1,2]. In activated cells, cPLA2K
undergoes Ca2þ-directed translocation from the cytosol to the
perinuclear membrane and endoplasmic reticulum (ER) [3], in
which downstream AA-metabolizing enzymes, including cy-
clooxygenases (COXs), 5-lipoxygenase (5-LO) and various ter-
minal PG and LT synthases, are also located [4^6]. This Ca2þ-
dependent translocation of cPLA2K depends entirely on the
N-terminal C2 domain [3]. In addition, phosphorylation of
cPLA2K by mitogen-activated protein kinases (MAPKs) and
other kinases is also crucial for its optimal activation [7].
The C2 domains bind the membrane in a Ca2þ-dependent
manner and thereby play an important role in Ca2þ-depen-
dent membrane targeting of peripheral proteins. Most C2 do-
mains have higher a⁄nity for anionic phosphatidylserine than
for zwitterionic phosphatidylcholine (PC), as exempli¢ed by
that of protein kinase CK (PKCK) [8]. In contrast, the C2
domain of cPLA2K preferentially binds to PC [9]. A recent
study using PKCK/cPLA2K chimeric mutants, in which their
C2 domains were interchanged, has demonstrated that the
plasma membrane translocation of PKCK and the perinuclear
translocation of cPLA2K in activated cells are crucially af-
fected by lipid selectivity of their C2 domains [10]. Addition-
ally, binding of the C2 domain of cPLA2K, but not that of
PKCK, to vimentin, a component of the intermediate ¢lament,
may also in£uence the intracellular localization of cPLA2K
[11].
An emerging body of evidence suggests that spatiotemporal
colocalization of eicosanoid-biosynthetic enzymes in the peri-
nuclear region is critical for their e¡ective functional coupling.
This appears to be true for coupling between intermediate
(COXs and 5-LO) and terminal enzymes in the AA cascade,
in which the unstable intermediate substrates, PGH2 and
LTA4, are transferred between these enzymes in proximity
[12,13]. However, considering that exogenous AA can be con-
verted to eicosanoids and that several sPLA2s, which often
release AA from the plasma membrane surface, can be func-
tionally linked to COXs and 5-LO [14^17], it has still re-
mained controversial whether the ‘perinuclear’ translocation
of cPLA2K is a prerequisite for its coupling with downstream
enzymes.
To address this critical issue, we designed experiments em-
ploying the aforementioned cPLA2K chimeric mutant possess-
ing the PKCK C2 domain (PKC(C2)). By comparing the cel-
lular AA-releasing and PGE2-synthetic capacities of wild-type
(WT) cPLA2K and the PKC(C2)-cPLA2K chimera, which
translocate to the perinuclear and plasma membranes, respec-
tively, upon cell activation [10], we provide evidence that the
perinuclear localization of cPLA2K is crucial, even if not es-
sential, for its functional coupling with COX enzymes.
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2. Materials and methods
2.1. Materials
Human embryonic kidney (HEK) 293 cells were cultured in RPMI
1640 medium (Nissui Pharmaceutical Co.) containing 10% (v/v) fetal
calf serum (FCS; Bioserum), as described previously [14]. cDNAs for
cPLA2K, COX-1 and COX-2 and HEK293 cells stably transfected
with these enzymes were described previously [14]. The enzyme im-
munoassay kit for PGE2 was purchased from Cayman Chemicals.
Goat anti-human COX-1 and COX-2 antibodies and rabbit anti-hu-
man cPLA2K antibody were purchased from Santa Cruz. A23187 was
purchased from Calbiochem. Human interleukin-1L (IL-1) was pur-
chased from Genzyme. Opti-MEM medium, Lipofectamine 2000 re-
agent, hygromycin and the mammalian expression vector pCDNA3.1/
hyg(3) were purchased from Invitrogen. Horseradish peroxidase-con-
jugated anti-goat and anti-rabbit antibodies were purchased from
Zymed. Rabbit anti-phospho-cPLA2K antibody, which recognizes
the MAPK-phosphorylated form of cPLA2K, was purchased from
Cell Signaling Technology.
2.2. Establishment of transfectants
Detailed procedures were described in our previous reports [14,15].
Brie£y, enhanced green £uorescent protein (EGFP)-tagged PKC(C2)-
cPLA2 cDNA [10] was subcloned into pCDNA3.1/hyg(3) and trans-
fected into COX-1- or COX-2-expressing HEK293 cells using Lipo-
fectamine 2000 in Opti-MEM medium. The cells were cloned by limit-
ing dilution in 96-well plates in cultured medium containing 7 Wg/ml
hygromycin. After culture for 3^4 weeks, wells containing a single
colony were chosen and expanded. Clones expressing appropriate lev-
els of each protein were screened by Western blotting and used in
subsequent studies.
2.3. Activation of HEK293 Cells
[3H]AA release and PGE2 production by cells after stimulation for
30 min with 10 WM A23187 (immediate response) and for 4 h with
IL-1 (delayed response) were assessed as described previously [14,15].
Brie£y, cells were prelabeled with [3H]AA (Amersham) (0.1 WCi/ml)
overnight, washed with fresh medium, and then incubated with 10 WM
A23187 in medium containing 1% FCS for 30 min or 1 ng/ml IL-1 in
medium containing 10% FCS for 30 min or 4 h. The percentage
[3H]AA release was calculated using the formula [S/(S+P)]U100,
where S and P are the radioactivity measured in the supernatant
and cell pellet, respectively. The supernatants from replicate cells
(without [3H]AA prelabeling) were subjected to the PGE2 enzyme
immunoassay.
2.4. Western blotting
Lysates from 105 cells were subjected to sodium dodecyl sulfate^
polyacrylamide gel electrophoresis using 7.5% gels under reducing
conditions. Transfer to nitrocellulose membranes and subsequent
Western blotting was performed as described previously [14]. Dilu-
tions of the ¢rst antibodies used in Western blotting were as follows:
anti-COX-1, 1:20 000; anti-COX-2, 1:2000; anti-cPLA2K, 1:5000;
and anti-phospho-cPLA2K, 1:1000.
Fig. 1. AA release by WT and chimeric cPLA2K. A: The expression of WT and chimeric cPLA2K proteins in parental cells and transfectants,
as assessed by Western blotting with an anti-cPLA2K antibody. B: AA release by cells transfected with WT cPLA2K or EGFP-PKC(C2)-
cPLA2K and control cells after stimulation for 30 min with 10 WM A23187. Values are meansUS.E.M. of three independent experiments. C:
Detection of the phosphorylated forms of WT cPLA2K and PKC(C2)-cPLA2K before (3) and after (+) activation with A23187, as assessed by
Western blotting with an anti-phospho-cPLA2K antibody. D: Subcellular localization of the WT (panels a and b) and chimeric (panels c and
d) cPLA2K in the transfectants before and after activation with A23187.
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2.5. Confocal laser microscopy
Cells grown on collagen-coated cover glasses (Iwaki Glass) were
¢xed with 3% paraformaldehyde for 30 min in phosphate-bu¡ered
saline (PBS). After three washes with PBS, the ¢xed cells were sequen-
tially treated with 1% (w/v) bovine serum albumin (for blocking) and
1% (w/v) saponin (for permeabilization) in PBS for 1 h, with anti-
cPLA2, COX-1 or COX-2 antibody (1:200 dilution) for 1 h in PBS
containing 1% albumin, and then with £uorescein isothiocyanate-goat
anti-rabbit or anti-goat IgG (1:200 dilution) for 1 h in PBS containing
1% albumin. After six washes with PBS, the cells were mounted on
glass slides using Perma Fluor (Japan Tanner), and the £uorescent
signals were visualized using a laser scanning confocal microscope
(IX70; Olympus), as described previously [13]. Localization of
EGFP-tagged PKC(C2)-cPLA2 was assessed by direct measurement
of the EGFP £uorescence, as described [10].
3. Results
3.1. AA release
WT cPLA2K and EGFP-fused PKC(C2)-cPLA2K were each
transfected into HEK293 cells. As reported previously, the
N-terminal EGFP tag does not a¡ect the function of cPLA2K
[10]. On immunoblotting with an anti-cPLA2K antibody, the
WT and chimera enzymes gave approximately 100- and 130-
kDa protein bands, respectively, with a similar intensity (Fig.
1A). A weak 100-kDa band observed in control cells and
EGFP-PKC(C2)-cPLA2K chimera-transfected cells corre-
sponded to cPLA2K expressed endogenously in HEK293 cells.
When these cells were stimulated with A23187 (Fig. 1B) or IL-
1 (data not shown), the AA-releasing responses of both cells
were almost equal, indicating that cPLA2K is able to release
AA from both the perinuclear and plasma membranes with
the same potency. Consistent with this, phosphorylation levels
of the WT and chimeric cPLA2K after cell activation, as as-
sessed by Western blotting using an antibody that recognizes
a phosphorylated form of cPLA2K on Ser505, were comparable
(Fig. 1C). The subcellular localization of the WT and chimeric
cPLA2K before and after cell activation, as assessed by con-
focal laser microscopy, is shown in Fig. 1D. Both the WT
(panel a) and chimeric (panel c) enzymes were distributed in
the cytosol before cell activation. After A23187 treatment, the
majority of the WT (panel b) and chimeric (panel d) enzymes
moved to the perinuclear envelope and the plasma membrane,
respectively (Fig. 1D), as reported previously [10].
3.2. COX coupling
We then transfected COX-1 or COX-2 into cells expressing
either WT cPLA2K or PKC(C2)-cPLA2K to assess their func-
tional coupling. Comparable expressions of COX-1 (Fig. 2A)
and COX-2 (Fig. 3A) in respective transfectants were veri¢ed
by Western blotting. The expression levels of the WT and
chimeric cPLA2K as well as AA release were una¡ected by
cotransfection of COX enzymes in these cells (data not
shown). Both COX-1 and COX-2 were located in the perinu-
clear envelope and the ER membrane in these transfectants,
with COX-1 being dispersed into the cytoplasm along the ER
membrane (Fig. 2B) and COX-2 being more enriched in the
perinuclear area (Fig. 3B). These COX distributions are in
agreement with previous studies [12,13].
Transfection of COX-1 alone modestly increased A23187-
induced immediate PGE2 generation (Fig. 2C), where AA is
supplied by endogenous cPLA2K [14]. Under the condition
Fig. 2. COX-1-dependent PGE2 production by WT and chimeric cPLA2K. A: The expression of COX-1 protein in parental cells and transfec-
tants, as assessed by Western blotting with anti-COX-1 antibody. B: Subcellular localization of COX-1 in the COX-1-transfected (panel a) and
-untransfected (panel b) cells. C: Cells were stimulated for 30 min with A23187 to assess immediate PGE2 production. Values are meansU
S.E.M. of three independent experiments.
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where WT and chimera enzymes displayed comparable AA
release as noted above, there was a marked increase in
PGE2 production in cells cotransfected with WT cPLA2K
and COX-1 relative to cells transfected with COX-1 alone,
whereas the PKC(C2)-cPLA2K chimera failed to augment
COX-1-directed PGE2 production (Fig. 2). This indicates
that COX-1 is unable to utilize the AA released from the
plasma membrane by PKC(C2)-cPLA2K in this setting. No
PGE2 production occurred via COX-1 in the IL-1-induced
delayed response, as previously reported [14,15].
Cells transfected with COX-2 alone modestly increased
both A23187-induced immediate (Fig. 3C) and IL-1-stimu-
lated (Fig. 3D) delayed PGE2-biosynthetic responses, which
were markedly augmented when WT cPLA2K was cotrans-
fected. Although cells cotransfected with PKC(C2)-cPLA2K
and COX-2 produced more PGE2 than cells expressing
COX-2 alone in both the A23187- and IL-1-stimulated re-
sponses, the amount of PGE2 produced by PKC(C2)-
cPLA2K/COX-2-cotransfected cells was signi¢cantly lower
than that produced by WT cPLA2K/COX-2-cotransfected
cells (Fig. 3). Thus, although COX-2-dependent PGE2 pro-
duction can occur even if AA is released at the plasma mem-
brane, the perinuclear AA is more e⁄ciently metabolized to
PGE2.
4. Discussion
Since many eicosanoid-biosynthetic enzymes, including
COXs, 5-LO and several terminal PG and LT synthases, are
localized in the perinuclear membrane and adjacent ER [4^6],
the translocation of cPLA2K into the same perinuclear com-
partment [3] seems reasonable in considering its role in sup-
plying AA to the proximal downstream enzymes. Kim et al.
[18] have recently shown that the AA released by cPLA2K at
the perinuclear membrane, but not the AA released by group
V sPLA2 at the plasma membrane, is metabolized to LTB4 via
Fig. 3. COX-2-dependent PGE2 production by WT and chimeric cPLA2K. A: The expression of COX-2 protein in parental cells and transfec-
tants, as assessed by Western blotting with anti-COX-2 antibody. B: Subcellular localization of COX-2 in the COX-2-transfected (panel a) and
-untransfected (panel b) cells. C,D: Cells were stimulated for 30 min with A23187 (C) or for 4 h with IL-1 (D) to assess immediate and delayed
PGE2 production, respectively. Values are meansUS.E.M. of three independent experiments.
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the perinuclear 5-LO in human neutrophils. Although this
study has provided some insights into the proposal that peri-
nuclear AA is favored over plasma membrane AA for eicosa-
noid biosynthesis, comparison of di¡erent types of PLA2
makes it di⁄cult to reach a de¢nitive conclusion for this hy-
pothesis. In this brief report, we performed analyses using a
particular cPLA2K mutant that translocates to the plasma
membrane upon cell activation [10], which allowed us to sub-
stantiate the biological importance of the perinuclear trans-
location of cPLA2K for the coupling with COXs. The results
obtained from this study are summarized in Fig. 4.
We show that the PKC(C2)-cPLA2K chimera, which trans-
locates to the plasma membrane [10], releases AA as e⁄ciently
as does WT cPLA2K in activated cells (Fig. 1). This is in line
with a previous report that a chimera of cPLA2K constitu-
tively targeted to the plasma membrane by the N-terminal
targeting sequence of the tyrosine kinase Lck leads to in-
creased AA release [19]. Even though the phospholipid com-
positions of the plasma membrane and the perinuclear mem-
brane may di¡er signi¢cantly, the ability of cPLA2K to
hydrolyze phospholipids without showing appreciable head
group selectivity [20] may permit its equivalent action on
both membranes.
Notably, distinct PGE2 production (i.e. COX coupling)
pro¢les between WT cPLA2K and PKC(C2)-cPLA2K, relative
to their comparable AA-releasing properties as noted above,
argue that the chimeric cPLA2K is less e⁄ciently coupled with
COXs than the WT enzyme. This is particularly evident when
combined with COX-1, since no PGE2 production by
PKC(C2)-cPLA2K via COX-1 occurred under the condition
where WT cPLA2K markedly increased PGE2 production
(Fig. 2). Unlike via COX-1, the PKC(C2)-cPLA2K chimera
increased PGE2 production via COX-2 to some extent, yet
it reached only about half the level of that by the WT enzyme
(Fig. 3). These results collectively suggest that the perinuclear
localization of cPLA2K is required for its optimal COX cou-
pling, even if not obligatory (particularly for COX-2 cou-
pling). A likely explanation for the di¡erence between COX-
1 and COX-2 observed here is due to their di¡erent AA sen-
sitivity in that COX-1 requires more AA than COX-2 to
function properly in cells [12^14]. Assuming that the AA re-
leased at the plasma membrane is less accessible to the peri-
nuclear COX enzymes, the local concentration of AA around
the perinuclear area may reach a level allowed for COX-2
catalysis but insu⁄cient for COX-1 action in this situation.
The notion obtained from this study can be applicable to
cellular AA-releasing and eicosanoid-biosynthetic actions of
other PLA2 enzymes, such as sPLA2s and iPLA2s. The fact
that the AA released from the plasma membrane can be me-
tabolized to PGE2, even though less e⁄ciently than that re-
leased from the perinuclear membrane, is in agreement with
the eicosanoid-biosynthetic function of the plasma membrane-
acting sPLA2s, such as group X sPLA2 [15,17]. Nonetheless,
although group X sPLA2 has the most potent AA-releasing
capability amongst the sPLA2 family, group IIA and V
sPLA2s, which can be internalized through the heparanoid-
shuttling mechanism and release AA around the perinuclear
region, exhibit comparable or even more PGE2-biosynthetic
capacity than does group X sPLA2 in HEK293 cells [17,21^
23], an observation reminiscent of our present study. Rela-
tively poor COX coupling of group VIA iPLA2, despite its
ability to markedly increase AA release, in HEK293 cells
[14,24] may re£ect that the membrane compartment on which
iPLA2 acts is distant from the perinuclear membrane.
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